Asthma and lower airway diseaseForced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values
Section snippets
Methods
We evaluated baseline lung function in relation to clinical and physiological outcome data from 2 National Heart, Lung, and Blood Institute Childhood Asthma Research and Education network studies: the PACT and the CLIC trial. PACT14 enrolled 413 children between the ages of 6 and 14 years with mild-to-moderate persistent asthma. There was a 2- to 4-week run-in period. The CLIC trial15 enrolled 191 children between the ages of 6 and 17 years with mild-to-moderate persistent asthma. There was a
Results
Table I shows the baseline characteristics of the CLIC trial and PACT cohorts. The PACT children were slightly younger and had a shorter duration of asthma, higher FEV1 percent predicted, higher FEF25-75 percent predicted, lower maximum bronchodilator response, lower methacholine response, and lower exhaled nitric oxide than the CLIC trial children.
Discussion
Asthma is characterized by inflammation of the large and small airways.25, 26 Small airway obstruction has been demonstrated in asthmatic subjects.27, 28, 29 FeNO is a measure of airway inflammation in asthma that has been associated with small airway obstruction.30 These 2 features of asthma are believed to be causally related. Air trapping in asthmatic subjects in the presence of normal FEV1 has been documented.3, 4 The midflow rates measured during spirometric testing are believed to
References (39)
- et al.
Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: assessment of response to methacholine and exercise challenge
J Allergy Clin Immunol
(2003) - et al.
Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry
Chest
(2006) - et al.
A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease
Am J Med
(1972) - et al.
Long-term comparison of three controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial (PACT)
J Allergy Clin Immunol
(2007) - et al.
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
J Allergy Clin Immunol
(2005) - et al.
Inflammation of small airways in asthma
J Allergy Clin Immunol
(1997) - et al.
Role of small airways in asthma: investigation using high-resolution computed tomography
J Allergy Clin Immunol
(2006) - et al.
Exhaled nitric oxide levels correlate with measures of disease control in asthma
J Allergy Clin Immunol
(2000) - et al.
Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients
Ann Allergy Asthma Immunol
(2003) - et al.
Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children
J Allergy Clin Immunol
(2003)
Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma
J Allergy Clin Immunol
Interpretative strategies for lung function tests
Eur Respir J
Standardisation of spirometry
Eur Respir J
Effects of asthma on pulmonary function in children. A longitudinal population-based study
Am Rev Respir Dis
Spirometry in the asthmatic child: is FEF25-75 a more sensitive test than FEV1/FVC?
Pediatr Pulmonol
FEF25-75 as a marker of airway obstruction in asthmatic children during reduced mite exposure at high altitude
J Asthma
Longitudinal study of pulmonary function development in childhood, adolescence, and early adulthood. Development of pulmonary function
Am Rev Respir Dis
Residual abnormalities of pulmonary function in asymptomatic young adult asthmatics with childhood-onset asthma
J Asthma
Simplified diagnosis of small-airway obstruction
N Engl J Med
Cited by (0)
Supported by grants 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036) and National Jewish (M01 RR00051).
Disclosure of potential conflict of interest: C. A. Sorkness is on advisory boards for GlaxoSmithKline, Schering-Plough, AstraZeneca, and Novartis and receives research support from Schering-Plough and Compleware/Sandoz. R. L. Lemanske is on the speakers' bureau for Merck, AstraZeneca, Doembecher Children's Hospital, Washington University, Medicus Group, Park Nicolet Institute, the American College of Allergy, Asthma & Immunology, the LA Allergy Society, Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), Children's Hospital of Minnesota, the Toronto Allergy Society, AAAAI, Beaumont Hospital (Detroit), the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, and New York Presbyterian; is a consultant for AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, International Meetings and Science, and Scienomics; is an author for Up-to-Date; and is a textbook editor for Elsevier, Inc. S. J. Szelfer has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boerhinger Ingelheim, Novartis, and Schering-Plough and receives research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI), NIH/National Institute of Allergy and Infectious Diseases, GlaxoSmithKline, the National Institute of Environmental Health Sciences, and the Environmental Protection Agency. L. B. Bacharier receives honoraria from AstraZeneca and serves on advisory boards for Genentech, GlaxoSmithKline, Merck, Schering-Plough, and Aerocrine. W. Morgan is a consultant for the Cystic Fibrosis Foundation, Genentech, and Novartis and receives research support from the National Institutes of Health/University of Wisconsin, and Novartis. The rest of the authors have declared that they have no conflict of interest.